2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Emerging Technologies, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Artificial Intelligence (AI), Computer Vision, Generative AI, Machine Learning, Natural Language Processing, Biological Processes, Apoptosis, Genomics, Microbiome, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Quality Improvement, Quality of Care, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

5646 Pseudo-Richter syndrome after cBTKi interruption in chronic lymphocytic leukemia: A distinct clinical entity responsive to BTKi reintroduction

Luca Laurenti Sr, MD, Annamaria Tomasso2, Tommaso Quaranta, MD3, Arianna Di Napoli, MD4, Francesca Perutelli, MD5, Alessandro Sanna, MD6, Paolo Sportoletti, MD, PhD7, Roberto Marasca, MD8, Riccardo Moia, MD, PhD9, Luca Stirparo10, Arianna Bakacs11, Valter Gattei, MD12, Dimitar Efremov, MD,PhD13, Andrea Visentin, MD, PhD14, Francesco Autore, MD15, Idanna Innocenti, MD, PhD16
1 Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, Università Cattolica del Sacro Cuore, Rome, Italy
2 Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, Università Cattolica del Sacro Cuore, Rome, Italy
3 Università Cattolica del Sacro Cuore, Rome, Italy
4 Sant' Andrea University Hospital, Sapienza University of Rome, Rome, Italy
5 University of Turin, AOU Città della Salute e della Scienza di Torino, Torino, Italy
6 AOU Careggi, Firenze, Italy
7 University of Perugia, Perugia, Italy
8 University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria Policlinico, Modena, Italy
9 University of Eastern Piedmont, Novara, Italy
10 Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, Università Cattolica del Sacro Cuore, Rome, Italy
11 Fondazione Policlinico Universitario 'Agostino Gemelli'- IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy
12 Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy
13 Macedonian Academy of Sciences and Arts, Skopje, Macedonia
14 University of Padua, Padova, Italy
15 Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
16 Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy

Background

Interruption or discontinuation of covalent Bruton tyrosine kinase inhibitors (cBTKi) may be followed by rapid disease flare in chronic lymphocytic leukemia (CLL). This phenomenon remains poorly characterized and may mimic Richter transformation (RT), potentially prompting invasive investigations or inappropriate treatment escalation. We aimed to describe the clinicobiological profile, clinical phenotype, management, and outcome of early withdrawal flare after cBTKi discontinuation.

Methods

In this retrospective multicenter study, consecutive patients with CLL who developed an early withdrawal flare after temporary or permanent cBTKi discontinuation between May 2019 and May 2026 were identified across six Italian centers. Demographic, biological, prior treatment, clinical, laboratory, imaging, histopathological, flare management, and outcome data were collected. Multiple flare episodes occurring in the same patient were analyzed separately.

Results

Thirteen flare episodes were identified in 12 patients from 6 Italian centers. The median age at cBTKi discontinuation was 75 years (range, 52–85), and 9/12 patients (75%) were male. IGHV was unmutated in 6/12 patients (50%); TP53 mutations were detected in 3/11 evaluable patients (27%), del(17p) in 3/12 (25%), and trisomy 12 in 4/12 (33%). CD49d was positive in 2/3 evaluable patients. cBTKi was administered as first-line therapy in 8/13 episodes (62%). Ibrutinib accounted for 10/13 episodes, zanubrutinib for 2/13 and acalabrutinib for 1/13. The median cBTKi exposure was 30 months (range, 4–67). At discontinuation, 11/13 episodes (85%) occurred in patients with controlled disease, including 1 complete response, 9 partial responses, and 1 stable disease, whereas 2/13 episodes (15%) occurred in patients with progressive disease.

Pseudo-RT developed after a median of 10 days following cBTKi withdrawal (range, 1–21). Rapid lymphadenopathy occurred in 11/13 episodes (85%), painful lymphadenopathy in 7/13 (54%), B symptoms in 6/13 (46%), LDH increase in 8/13 (62%), progressive lymphocytosis in 7/13 (54%), worsening cytopenias in 5/13 (38%), and increasing splenomegaly in 4/13 (31%). Clinical features suspicious for RT were present in 8/13 episodes (62%). Five patients underwent lymph node biopsy, all of which were locally misinterpreted as diffuse large B-cell lymphoma type RT. Despite these findings, no patient received chemoimmunotherapy, venetoclax, or anti-CD20 therapy.

A BTKi was reintroduced in all 13 episodes: the same cBTKi in 10 and pirtobrutinib in 3. Corticosteroids were administered in 4/13 episodes (31%). The flare resolved in all cases, with a median time to resolution of 9.5 days (range, 2–30) among the 12 evaluable episodes.

Conclusions

Pseudo-RT is a newly recognized entity characterized by rapid and often painful lymphadenopathy, LDH elevation and progressive lymphocytosis occurring within  21 days of  cBTKi withdrawal. This syndrome frequently mimics RT, including biopsy findings misinterpreted as DLBCL-RT.  Prompt reintroduction of a BTKi, with or without corticosteroids, led to flare resolution in all patients. Awareness of this entity is essential to distinguish pseudo-RT  from true RT and may prevent inappropriate therapeutic escalation. Prospective studies  incorporating centralized pathology review, FISH analysis and molecular profiling are underway to better define the clinicobiological features of CLL patients receiving cBTKi who are at risk of developing pseudo-RT.

Luca Laurenti Sr, MD: AbbVie - Consultancy (Includes expert testimony); BeOne - Consultancy (Includes expert testimony)